SCHEMBL4900873

SCHEMBL4900873

CCc1ccc(S(=O)(=O)NCCc2coc(-c3ccc(C(F)(F)F)cc3)n2)cc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.52
PPARA Q07869 3/20 0.52
POLB P06746 2/20 0.45
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45
KDM1A O60341 3/20 0.40
ACLY P53396 1/20 0.39
MMP1 P03956 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 1/20 0.37
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
IDH2 P48735 1/20 0.36
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36
S1PR1 P21453 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4903596 0.92 PPARG (0.50) PPARGPPARAPOLBLMNASMN1; SMN2
SCHEMBL4899812 0.92 PPARG (0.43) PPARGPPARAPOLBLMNASMN1; SMN2
SCHEMBL4906505 0.90 LMNA (0.46) PPARGPPARAPOLBLMNASMN1; SMN2
SCHEMBL4911898 0.86 PPARG (0.44) PPARGPPARAPOLBLMNASMN1; SMN2
SCHEMBL4906842 0.85 LMNA (0.45) PPARGPPARAPOLBLMNASMN1; SMN2
SCHEMBL4906000 0.84 PPARG (0.41) PPARGPPARAPOLBLMNASMN1; SMN2
SCHEMBL4897574 0.82 LMNA (0.47) PPARGPPARAPOLBLMNASMN1; SMN2
SCHEMBL4903863 0.80 PPARG (0.42) PPARGPPARAPOLBLMNASMN1; SMN2
SCHEMBL4895920 0.80 LMNA (0.41) PPARGPPARAPOLBLMNASMN1; SMN2
SCHEMBL4899406 0.79 MAPT (0.45) PPARGPPARAPOLBLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD PPARG 2/4885PPARA 1/4885POLB 1807/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD PPARG 2/4885PPARA 1/4885POLB 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.